Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study on the Safety, Tolerability and Pharmacokinetic Characteristics of a Single Dose of GMDTC Administered to Healthy Subjects for Injection

NCT05908383 is registered in ClinicalTrials.gov with Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT05908383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05908383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study on the Safety, Tolerability and Pharmacokinetic Characteristics of a Single Dose of GMDTC Administered to Healthy Subjects for Injection
Lead sponsor
Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 30, 2023
Completion date
July 30, 2023
Enrollment
76 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cadmium exposure